45 CFR § 180 compliance
A · 100
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
●Min / max negotiated charges
●Free, public, no login required
Procedures listed
11,000
Insurances with rates
12
CPT / HCPCS codes
7,408
Source MRF
Most expensive procedures (gross)
J0225
$286,442
VUTRISIRAN 25 MG/0.5 ML SUBCUTANEOUS SYRINGE
Gross
$596,755
J0225
$286,442
VUTRISIRAN 25 MG/0.5 ML SUBCUTANEOUS SYRINGE
Gross
$596,755
A9513
$114,000
LUTETIUM LU 177 DOTATATE 10 MCI/ML (370 MBQ/ML) INTRAVENOUS SOLUTION
Gross
$237,500
A9513
$114,000
LUTETIUM LU 177 DOTATATE 10 MCI/ML (370 MBQ/ML) INTRAVENOUS SOLUTION
Gross
$237,500
J1823
$104,800
INEBILIZUMAB-CDON 10 MG/ML INTRAVENOUS SOLUTION
Gross
$218,333
J1823
$104,800
INEBILIZUMAB-CDON 10 MG/ML INTRAVENOUS SOLUTION
Gross
$218,333
J2351
$99,077
OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23000 UNIT/23 ML SUBCUT SOLN
Gross
$206,410
J2351
$99,077
OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23000 UNIT/23 ML SUBCUT SOLN
Gross
$206,410
C9293
$98,818
GLUCARPIDASE 1000 UNIT INTRAVENOUS SOLUTION
Gross
$205,870
C9293
$98,818
GLUCARPIDASE 1000 UNIT INTRAVENOUS SOLUTION
Gross
$205,870
J9228
$85,221
IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION
Gross
$177,544
J9228
$85,221
IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION
Gross
$177,544
J1747
$61,360
SPESOLIMAB-SBZO 60 MG/ML INTRAVENOUS SOLUTION
Gross
$127,833
J1747
$61,360
SPESOLIMAB-SBZO 60 MG/ML INTRAVENOUS SOLUTION
Gross
$127,833
J2327
$51,840
RISANKIZUMAB-RZAA 150 MG/ML SUBCUTANEOUS SYRINGE
Gross
$108,000
J2327
$51,840
RISANKIZUMAB-RZAA 150 MG/ML SUBCUTANEOUS SYRINGE
Gross
$108,000
J2350
$47,314
OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION
Gross
$98,572
J2350
$47,314
OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION
Gross
$98,572
J9309
$43,366
POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION
Gross
$90,347
J9309
$43,366
POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION
Gross
$90,347
J0638
$41,097
CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION
Gross
$85,619
J0638
$41,097
CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION
Gross
$85,619
J9334
$37,855
EFGARTIGIMOD ALFA 1008 MG-HYALURON-QVFC 11200 UNIT/5.6 ML SUBCUT SOLN
Gross
$78,865
J9334
$37,855
EFGARTIGIMOD ALFA 1008 MG-HYALURON-QVFC 11200 UNIT/5.6 ML SUBCUT SOLN
Gross
$78,865
J3241
$37,132
TEPROTUMUMAB-TRBW 500 MG INTRAVENOUS SOLUTION
Gross
$77,358
J3241
$37,132
TEPROTUMUMAB-TRBW 500 MG INTRAVENOUS SOLUTION
Gross
$77,358
J2507
$36,926
PEGLOTICASE 8 MG/ML INTRAVENOUS SOLUTION
Gross
$76,930
J2507
$36,926
PEGLOTICASE 8 MG/ML INTRAVENOUS SOLUTION
Gross
$76,930
J9298
$34,878
NIVOLUMAB 240 MG-RELATLIMAB-RMBW 80 MG/20 ML INTRAVENOUS SOLUTION
Gross
$72,662
J9298
$34,878
NIVOLUMAB 240 MG-RELATLIMAB-RMBW 80 MG/20 ML INTRAVENOUS SOLUTION
Gross
$72,662
J1628
$33,736
GUSELKUMAB 200 MG/2 ML SUBCUTANEOUS SYRINGE
Gross
$70,283
J1628
$33,736
GUSELKUMAB 200 MG/2 ML SUBCUTANEOUS SYRINGE
Gross
$70,283
J3245
$31,963
TILDRAKIZUMAB-ASMN 100 MG/ML SUBCUTANEOUS SYRINGE
Gross
$66,589
J3245
$31,963
TILDRAKIZUMAB-ASMN 100 MG/ML SUBCUTANEOUS SYRINGE
Gross
$66,589
J3357
$29,029
USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SOLUTION
Gross
$60,477
J3357
$29,029
USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SOLUTION
Gross
$60,477
J9042
$28,181
BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION
Gross
$58,710
J9042
$28,181
BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION
Gross
$58,710
J9272
$27,207
DOSTARLIMAB-GXLY 50 MG/ML INTRAVENOUS SOLUTION
Gross
$56,682
J9272
$27,207
DOSTARLIMAB-GXLY 50 MG/ML INTRAVENOUS SOLUTION
Gross
$56,682
J9043
$27,099
CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION
Gross
$56,456
J9043
$27,099
CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION
Gross
$56,456
J9022
$27,004
ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION
Gross
$56,259
J9022
$27,004
ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION
Gross
$56,259
J1640
$26,257
HEMIN 350 MG INTRAVENOUS POWDER FOR SOLUTION
Gross
$54,702
J1640
$26,257
HEMIN 350 MG INTRAVENOUS POWDER FOR SOLUTION
Gross
$54,702
J9144
$25,246
DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN
Gross
$52,595
J9144
$25,246
DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN
Gross
$52,595
J2329
$25,134
UBLITUXIMAB-XIIY 25 MG/ML INTRAVENOUS SOLUTION
Gross
$52,363
J2329
$25,134
UBLITUXIMAB-XIIY 25 MG/ML INTRAVENOUS SOLUTION
Gross
$52,363
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J0225 | VUTRISIRAN 25 MG/0.5 ML SUBCUTANEOUS SYRINGE | $596,755 | $286,442 | $358,053 | $584,820 | 19 |
| J0225 | VUTRISIRAN 25 MG/0.5 ML SUBCUTANEOUS SYRINGE | $596,755 | $286,442 | $256,605 | $584,820 | 30 |
| A9513 | LUTETIUM LU 177 DOTATATE 10 MCI/ML (370 MBQ/ML) INTRAVENOUS SOLUTION | $237,500 | $114,000 | $142,500 | $232,750 | 19 |
| A9513 | LUTETIUM LU 177 DOTATATE 10 MCI/ML (370 MBQ/ML) INTRAVENOUS SOLUTION | $237,500 | $114,000 | $279 | $232,750 | 32 |
| J1823 | INEBILIZUMAB-CDON 10 MG/ML INTRAVENOUS SOLUTION | $218,333 | $104,800 | $131,000 | $213,966 | 19 |
| J1823 | INEBILIZUMAB-CDON 10 MG/ML INTRAVENOUS SOLUTION | $218,333 | $104,800 | $474 | $213,966 | 32 |
| J2351 | OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23000 UNIT/23 ML SUBCUT SOLN | $206,410 | $99,077 | $123,846 | $202,281 | 19 |
| J2351 | OCRELIZUMAB 920 MG-HYALURONIDASE-OCSQ 23000 UNIT/23 ML SUBCUT SOLN | $206,410 | $99,077 | $88,756 | $202,281 | 30 |
| C9293 | GLUCARPIDASE 1000 UNIT INTRAVENOUS SOLUTION | $205,870 | $98,818 | $123,522 | $201,753 | 19 |
| C9293 | GLUCARPIDASE 1000 UNIT INTRAVENOUS SOLUTION | $205,870 | $98,818 | $385 | $201,753 | 32 |
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $177,544 | $85,221 | $106,526 | $173,993 | 19 |
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $177,544 | $85,221 | $189 | $173,993 | 32 |
| J1747 | SPESOLIMAB-SBZO 60 MG/ML INTRAVENOUS SOLUTION | $127,833 | $61,360 | $76,700 | $125,276 | 19 |
| J1747 | SPESOLIMAB-SBZO 60 MG/ML INTRAVENOUS SOLUTION | $127,833 | $61,360 | $54,968 | $125,276 | 30 |
| J2327 | RISANKIZUMAB-RZAA 150 MG/ML SUBCUTANEOUS SYRINGE | $108,000 | $51,840 | $64,800 | $105,840 | 19 |
| J2327 | RISANKIZUMAB-RZAA 150 MG/ML SUBCUTANEOUS SYRINGE | $108,000 | $51,840 | $46,440 | $105,840 | 30 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $98,572 | $47,314 | $59,143 | $96,600 | 19 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $98,572 | $47,314 | $58.76 | $96,600 | 32 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $90,347 | $43,366 | $54,208 | $88,540 | 19 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $90,347 | $43,366 | $136 | $88,540 | 32 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $85,619 | $41,097 | $51,371 | $83,906 | 19 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $85,619 | $41,097 | $124 | $83,906 | 32 |
| J9334 | EFGARTIGIMOD ALFA 1008 MG-HYALURON-QVFC 11200 UNIT/5.6 ML SUBCUT SOLN | $78,865 | $37,855 | $47,319 | $77,288 | 19 |
| J9334 | EFGARTIGIMOD ALFA 1008 MG-HYALURON-QVFC 11200 UNIT/5.6 ML SUBCUT SOLN | $78,865 | $37,855 | $33,912 | $77,288 | 30 |
| J3241 | TEPROTUMUMAB-TRBW 500 MG INTRAVENOUS SOLUTION | $77,358 | $37,132 | $46,415 | $75,811 | 19 |
| J3241 | TEPROTUMUMAB-TRBW 500 MG INTRAVENOUS SOLUTION | $77,358 | $37,132 | $333 | $75,811 | 32 |
| J2507 | PEGLOTICASE 8 MG/ML INTRAVENOUS SOLUTION | $76,930 | $36,926 | $46,158 | $75,391 | 19 |
| J2507 | PEGLOTICASE 8 MG/ML INTRAVENOUS SOLUTION | $76,930 | $36,926 | $3,392 | $75,391 | 32 |
| J9298 | NIVOLUMAB 240 MG-RELATLIMAB-RMBW 80 MG/20 ML INTRAVENOUS SOLUTION | $72,662 | $34,878 | $43,597 | $71,209 | 19 |
| J9298 | NIVOLUMAB 240 MG-RELATLIMAB-RMBW 80 MG/20 ML INTRAVENOUS SOLUTION | $72,662 | $34,878 | $31,245 | $71,209 | 30 |
| J1628 | GUSELKUMAB 200 MG/2 ML SUBCUTANEOUS SYRINGE | $70,283 | $33,736 | $42,170 | $68,877 | 19 |
| J1628 | GUSELKUMAB 200 MG/2 ML SUBCUTANEOUS SYRINGE | $70,283 | $33,736 | $139 | $68,877 | 32 |
| J3245 | TILDRAKIZUMAB-ASMN 100 MG/ML SUBCUTANEOUS SYRINGE | $66,589 | $31,963 | $39,953 | $65,257 | 19 |
| J3245 | TILDRAKIZUMAB-ASMN 100 MG/ML SUBCUTANEOUS SYRINGE | $66,589 | $31,963 | $140 | $65,257 | 32 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SOLUTION | $60,477 | $29,029 | $36,286 | $59,268 | 19 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SOLUTION | $60,477 | $29,029 | $153 | $59,268 | 32 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $58,710 | $28,181 | $35,226 | $57,536 | 19 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $58,710 | $28,181 | $253 | $57,536 | 32 |
| J9272 | DOSTARLIMAB-GXLY 50 MG/ML INTRAVENOUS SOLUTION | $56,682 | $27,207 | $34,009 | $55,548 | 19 |
| J9272 | DOSTARLIMAB-GXLY 50 MG/ML INTRAVENOUS SOLUTION | $56,682 | $27,207 | $24,373 | $55,548 | 30 |
| J9043 | CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION | $56,456 | $27,099 | $33,874 | $55,327 | 19 |
| J9043 | CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION | $56,456 | $27,099 | $232 | $55,327 | 32 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $56,259 | $27,004 | $33,755 | $55,134 | 19 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $56,259 | $27,004 | $91.86 | $55,134 | 32 |
| J1640 | HEMIN 350 MG INTRAVENOUS POWDER FOR SOLUTION | $54,702 | $26,257 | $32,821 | $53,608 | 19 |
| J1640 | HEMIN 350 MG INTRAVENOUS POWDER FOR SOLUTION | $54,702 | $26,257 | $31.35 | $53,608 | 32 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $52,595 | $25,246 | $31,557 | $51,543 | 19 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $52,595 | $25,246 | $53.4 | $51,543 | 32 |
| J2329 | UBLITUXIMAB-XIIY 25 MG/ML INTRAVENOUS SOLUTION | $52,363 | $25,134 | $31,418 | $51,315 | 19 |
| J2329 | UBLITUXIMAB-XIIY 25 MG/ML INTRAVENOUS SOLUTION | $52,363 | $25,134 | $22,516 | $51,315 | 30 |
Showing top 50 of 11,000 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.